Actively Recruiting
Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
Led by University of Miami · Updated on 2026-03-02
26
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
Sponsors
U
University of Miami
Lead Sponsor
A
ADC Therapeutics S.A.
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to determine whether combining Loncastuximab Tesirine with Epcoritamab is tolerable and effective for reducing and/or eliminating lymphoma cells in the body.
CONDITIONS
Official Title
Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men and women aged 18 years or older
- Able and willing to sign informed consent
- Able to follow trial protocol
- Diagnosed with relapsed or refractory large B-cell lymphoma based on 2016 WHO classification
- Received at least one prior systemic therapy including anti-CD20 monoclonal antibody and anthracycline
- Measurable disease per 2014 Lugano Classification with nodal or extranodal lesions
- ECOG performance status 0 to 2
- Adequate blood counts and liver and kidney function within 6 weeks before therapy
- Willing to avoid pregnancy during trial and for 12 months afterward
- Stable HIV patients on treatment with adequate CD4 count and viral load
- Life expectancy of at least 12 weeks
- Glucocorticoid treatment tapered to maximum 25 mg daily in last 14 days before first epcoritamab dose
You will not qualify if you...
- Primary central nervous system lymphoma or known CNS lymphoma involvement
- Prior anti-CD19 CAR-T therapy
- Prior bispecific T-cell engaging antiCD20XCD3 antibody treatment
- Prior autologous or allogenic stem cell transplant
- Significant lung disease affecting exercise tolerance
- Significant heart disease including recent unstable angina, heart attack, or severe heart failure
- Pregnant or breastfeeding
- Not recovered from major surgery complications/toxicities
- Active infection requiring systemic treatment or recent major infection
- Recent live vaccine exposure or need for live vaccine during study
- Active hepatitis B or C infection not controlled
- Active COVID-19 infection
- Severe chronic pulmonary disease or other serious conditions limiting study tolerance
- Seizure disorder with recent convulsions
- Impaired decision-making capacity
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Miami
Miami, Florida, United States, 33136
Actively Recruiting
Research Team
J
Juan Alderuccio, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here